

# EXHIBIT 22

IN THE UNITED STATES DISTRICT COURT  
MIDDLE DISTRICT OF FLORIDA  
ORLANDO DIVISION

- - -

IN RE: SEROQUEL : CASE NO.  
PRODUCTS LIABILITY :  
LITIGATION : 6:06-md-01769-ACC-DAB  
:  
MDL Docket No. 1769:

- - -

May 13, 2008

- - -

C O N F I D E N T I A L

- - -

Continued videotape deposition of  
MARGARET MELVILLE, taken pursuant to  
notice, was held at the offices of Golkow  
Technologies, Inc., One Liberty Place,  
51st Floor, 1650 Market Street,  
Philadelphia, Pennsylvania 19103,  
commencing at 9:13 a.m., on the above  
date, before Linda Rossi Rios, RPR, CCR  
and Notary Public.

- - -

Golkow Technologies, Inc.  
One Liberty Place, 51st Floor  
1650 Market Street  
Philadelphia, Pennsylvania 19103  
877.370.3377

Page 481

1 starts on page 79 -- I'm sorry, starts on  
2 page 78 is titled, "Assessment of the  
3 possibility of a causal association  
4 between Seroquel treatment and  
5 disturbances in glucose regulation."  
6 Plasma glucose data from clinical Studies  
7 40 and 41 -- I mean, 43, excuse me. 41  
8 and 43.  
9 A. 41 and 43, yes.  
10 Q. Turn over to page 81.  
11 A. These are your internal  
12 numbers?  
13 Q. Yes.  
14 A. Okay.  
15 Q. I'm at 2.2.1. Are you with  
16 me?  
17 A. Yes.  
18 Q. In both studies, the  
19 investigators were instructed to obtain  
20 blood glucose samples under fasting  
21 conditions at screening and at endpoint.  
22 That was the protocol. Correct?  
23 And then turn over to page  
24 82. Although the investigators in

Page 482

1 studies 41 and 43 were instructed to  
2 obtain blood glucose samples under  
3 fasting conditions, it appears that that  
4 was not entirely successful, as a high  
5 proportion of the glucose samples were  
6 taken after 10:00 a.m., especially at  
7 endpoint. Did I read that reasonably  
8 correctly?  
9 A. Yes.  
10 Q. All right. So we have  
11 now two --  
12 MR. GOLDMAN: Can you read  
13 the next sentence for completion,  
14 Mr. Pirtle?  
15 BY MR. PIRTLE:  
16 Q. See Appendix B.  
17 MR. GOLDMAN: The next  
18 sentence.  
19 THE WITNESS: The next  
20 sentence.  
21 BY MR. PIRTLE:  
22 Q. "This, coupled with the  
23 large magnitude of some of the absolute  
24 values and changes from baseline, and the

Page 483

1 fact that patients were outpatients at  
2 endpoint, indicates that it is unlikely  
3 that the majority of patients were truly  
4 fasted." Did I read that correctly?  
5 A. Yes.  
6 Q. All right. So now we have  
7 two studies, both studies, studies  
8 designed to draw fasting blood glucose.  
9 Correct?  
10 MR. GOLDMAN: Object to the  
11 form.  
12 BY MR. PIRTLE:  
13 Q. 41 and 43?  
14 A. Studies 41 and 43 were  
15 protocolled to have investigators collect  
16 fasted plasma glucose levels.  
17 Q. And the investigators in the  
18 study, to your knowledge, followed the  
19 protocol, didn't it?  
20 MR. GOLDMAN: Object to the  
21 form.  
22 THE WITNESS: I don't -- I  
23 don't have the answer to that.  
24 BY MR. PIRTLE:

Page 484

1 Q. All right. Well, a  
2 determination was made internal at  
3 AstraZeneca that looking at the  
4 information from the studies,  
5 particularly at the end draw, that some  
6 of the draws were done after 10:00 a.m.  
7 for both studies. Right?  
8 MR. GOLDMAN: Object to the  
9 form.  
10 THE WITNESS: I don't -- I  
11 mean, I'm reading the conclusion  
12 from the sentences on page 82.  
13 BY MR. PIRTLE:  
14 Q. Okay. I've got it up for  
15 the jury. It says, Although the  
16 investigators..., and we're talking about  
17 study 41 and 43, were ...instructed to  
18 obtain blood glucose samples under  
19 fasting conditions, it appears that that  
20 was not entirely successful..., and I've  
21 stopped, because I'm fixing to ask a  
22 question. Are you with me?  
23 A. Yes.  
24 Q. All right. The protocol for

Page 485

1 41 and 43 says draw fasting blood glucose  
2 and because for one reason AstraZeneca  
3 internally determined that some of the  
4 blood was drawn after 10:00 a.m., and  
5 two, because there was high values,  
6 AstraZeneca decided that the patients  
7 probably weren't fasted. Is that true?  
8 A. That's my recollection.  
9 Q. So even though the protocol  
10 says for the investigators to draw  
11 fasting blood glucose levels, internally  
12 at AstraZeneca, because one, some of the  
13 samples were taken after 10:00 a.m., and  
14 two, some of the values were high, an  
15 internal decision was made at AstraZeneca  
16 that this is probably nonfasting blood  
17 levels?  
18 MR. GOLDMAN: Objection.  
19 Asked and answered. That is  
20 almost identical to the previous  
21 question. So asked and answered.  
22 MR. PIRTLE: I'm trying to  
23 make sure I understand.  
24 BY MR. PIRTLE:

Page 486

1 Q. Do I have a clear  
2 understanding?  
3 A. Yes.  
4 Q. Now, both studies, 40 and  
5 41, under the --  
6 MR. LAMINACK: 41 and 43.  
7 MR. PIRTLE: 41 and 43,  
8 thank you, Rick.  
9 BY MR. PIRTLE:  
10 Q. Under the protocols as  
11 developed by AstraZeneca, both 41 and 43  
12 were positive for elevated blood glucose  
13 at 126 -- greater than or equal to  
14 126 milliliters per deciliter. Correct?  
15 MR. GOLDMAN: Object to the  
16 form.  
17 THE WITNESS: I recall the  
18 overall conclusions from study 41.  
19 BY MR. PIRTLE:  
20 Q. How about 43, it was  
21 positive also, wasn't it?  
22 A. I don't recall. I'd have to  
23 review the document.  
24 Q. You don't remember what 43

Page 487

1 said, but you remember 43, at least one  
2 arm you remember being positive at 126?  
3 MR. GOLDMAN: Object to the  
4 form.  
5 THE WITNESS: I remember the  
6 results of trial 141. It looks to  
7 me, from what was written here,  
8 that we didn't use the 126  
9 measurement, that we used the 200  
10 measurement because we had an  
11 understanding, the clinical team  
12 had reached a conclusion that the  
13 patients weren't fasted.  
14 BY MR. PIRTLE:  
15 Q. You're going to my next  
16 point. I'm asking first under the 126  
17 standard as the protocol, the directions  
18 for the study as was originally designed,  
19 both 1 -- both study 41 and 43 were  
20 positive for elevated blood glucose.  
21 Correct?  
22 MR. GOLDMAN: Object to the  
23 form.  
24 THE WITNESS: I'd have to

Page 488

1 look at the conclusions in this  
2 report, Mr. Pirtle.  
3 BY MR. PIRTLE:  
4 Q. Do you believe that the  
5 non -- I mean that the 126 standard for  
6 fasting blood glucose is in that report?  
7 MR. GOLDMAN: Object to the  
8 form.  
9 THE WITNESS: Looking at  
10 page 85, and I see a row that I  
11 think reflects that --  
12 BY MR. PIRTLE:  
13 Q. Okay?  
14 A. -- for trial 41.  
15 Q. Was 41 positive?  
16 MR. GOLDMAN: Object to the  
17 form.  
18 BY MR. PIRTLE:  
19 Q. At 126?  
20 A. And positive means are there  
21 patients with values greater than 126?  
22 Q. Yes.  
23 A. Mgs per deciliter?  
24 Q. Yes.